Risk factors for locoregional recurrence in patients with resected N1 non-small cell lung cancer: a retrospective study to identify patterns of failure and implications for adjuvant radiotherapy

被引:10
作者
Fan, Chengcheng [1 ,2 ]
Gao, Shugeng [2 ,3 ]
Hui, Zhouguang [1 ,2 ]
Liang, Jun [1 ,2 ]
Lv, Jima [1 ,2 ]
Wang, Xiaozhen [1 ,2 ]
He, Jie [2 ,3 ]
Wang, Luhua [1 ,2 ]
机构
[1] Chinese Acad Med Sci, Canc Hosp & Inst, Dept Radiat Oncol, Beijing 10021, Peoples R China
[2] Peking Union Med Coll, Beijing 10021, Peoples R China
[3] Chinese Acad Med Sci, Canc Hosp & Inst, Dept Thorac Surg, Beijing 10021, Peoples R China
来源
RADIATION ONCOLOGY | 2013年 / 8卷
关键词
Non-small cell lung cancer; Locoregional recurrence; Survival; N1; stage; Postoperative radiotherapy; TRIALIST ASSOCIATION ANITA; POSTOPERATIVE RADIOTHERAPY; RADIATION-THERAPY; LYMPH-NODES; STAGE-II; LOCAL FAILURE; SURVIVAL; CARCINOMA; NUMBER; CISPLATIN;
D O I
10.1186/1748-717X-8-286
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Meta-analysis of randomized trials has shown that postoperative radiotherapy (PORT) had a detrimental effect on overall survival (OS) in patients with resected N1 non-small cell lung cancer (NSCLC). Conversely, the locoregional recurrence (LR) rate is reported to be high without adjuvant PORT in these patients. We have evaluated the pattern of failure, actuarial risk and risk factors for LR in order to identify the subset of N1 NSCLC patients with the highest risk of LR. These patients could potentially benefit from PORT. Methods: We conducted a retrospective study on 199 patients with pathologically confirmed T1-3N1M0 NSCLC who underwent surgery. None of the patients had positive surgical margins or received preoperative therapy or PORT. The median follow-up was 53.8 months. Complete mediastinal lymph node (MLN) dissection and examination was defined as >= 3 dissected and examined MLN stations; incomplete MLN dissection or examination (IMD) was defined as <3 dissected or examined MLN stations. The primary end point of this study was freedom from LR (FFLR). Differences between patient groups were compared and risk factors for LR were identified by univariate and multivariate analyses. Results: LR was identified in 41 (20.6%) patients, distant metastasis (DM) was identified in 79 (39.7%) patients and concurrent LR and DM was identified in 25 (12.6%) patients. The 3- and 5-year OS rates in patients with resected N1 NSCLC were 78.4% and 65.6%, respectively. The corresponding FFLR rates were 80.8% and 77.3%, respectively. Univariate analyses identified that nonsmokers, <= 23 dissected lymph nodes, visceral pleural invasion and lymph node ratio >10% were significantly associated with lower FFLR rates (P < 0.05). Multivariate analyses further confirmed positive lymph nodes at station 10 and IMD as risk factors for LR (P < 0.05). The 5-year LR rate was highest in patients with both these risk factors (48%). Conclusions: The incidence of LR in patients with surgically resected T1-3N1M0 NSCLC is high. Patients with IMD and positive lymph nodes at station 10 have the highest risk of LR, and may therefore benefit from adjuvant PORT. Further investigations of PORT in this subset of patients are warranted.
引用
收藏
页数:9
相关论文
共 50 条
  • [21] Prognostic Factors for Resected Non-Small Cell Lung Cancer with pN2 Status: Implications for Use of Postoperative Radiotherapy
    Moretti, Luigi
    Yu, David S.
    Chen, Heidi
    Carbone, David P.
    Johnson, David H.
    Keedy, Vicki L.
    Putnam, Joe B., Jr.
    Sandler, Alan B.
    Shyr, Yu
    Lu, Bo
    ONCOLOGIST, 2009, 14 (11) : 1106 - 1115
  • [22] The Role of Adjuvant Radiotherapy for Resected Non-Small Cell Lung Cancer in the Modern Era
    Lin, Steven H.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 104 (04): : 712 - 713
  • [23] Use and Impact of Adjuvant Chemotherapy in Patients With Resected Non-Small Cell Lung Cancer
    Williams, Christina D.
    Gajra, Ajeet
    Ganti, Apar K.
    Kelley, Michael J.
    CANCER, 2014, 120 (13) : 1939 - 1947
  • [24] Selection of proper candidates with resected pathological stage IIIA-N2 non-small cell lung cancer for postoperative radiotherapy
    Hui, Zhouguang
    Dai, Honghai
    Liang, Jun
    Lv, Jima
    Zhou, Zongmei
    Feng, Qinfu
    Xiao, Zefen
    Chen, Dongfu
    Zhang, Hongxing
    Yin, Weibo
    Wang, Luhua
    THORACIC CANCER, 2015, 6 (03) : 346 - 353
  • [25] Local treatment of oligometastatic recurrence in patients with resected non-small cell lung cancer
    Yano, Tokujiro
    Okamoto, Tatsuro
    Haro, Akira
    Fukuyama, Seiichi
    Yoshida, Tsukihisa
    Kohno, Mikihiro
    Maehara, Yoshihiko
    LUNG CANCER, 2013, 82 (03) : 431 - 435
  • [26] Survival After Adjuvant Chemotherapy in Completely Resected N1 Non-Small Cell Lung Cancer
    Wang, E.
    Bourdages-Pageau, E.
    Gagnon, H.
    Labbe, C.
    Tremblay, L.
    Ugalde, P.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S633 - S633
  • [27] A biomarker-based prediction model for risk of locoregional recurrence in pathologic stage IIIA-N2 non-small cell lung cancer
    Jiang, Guicheng
    Huang, Junpeng
    Cui, Tongjian
    Lin, Xing
    Lin, Guishan
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2020, 13 (12): : 3060 - 3082
  • [28] Prognostic factors in patients with postoperative brain recurrence from completely resected non-small cell lung cancer
    Kanou, Takashi
    Okami, Jiro
    Tokunaga, Toshiteru
    Ishida, Daisuke
    Kuno, Hidenori
    Higashiyama, Masahiko
    THORACIC CANCER, 2015, 6 (01) : 38 - 42
  • [29] Local failure after complete resection of N0-1 non-small cell lung cancer
    Saynak, Mert
    Veeramachaneni, Nirmal K.
    Hubbs, Jessica L.
    Nam, Jiho
    Qaqish, Bahjat F.
    Bailey, Janet E.
    Chung, Wonil
    Marks, Lawrence B.
    LUNG CANCER, 2011, 71 (02) : 156 - 165
  • [30] Prognostic factors for recurrence in patients with surgically resected non-small cell lung cancer
    Moskalenko, Yuliia
    Smorodska, Olga
    Deineka, Volodymyr
    Kravets, Oleksandr
    Moskalenko, Roman
    WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY, 2022, 26 (03): : 239 - 246